Data as of Apr 22
| +0.025 / +2.21%|
Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY.
|Russell H. Ellison||Chairman, President & Chief Executive Officer|
|David J. Barrett||Chief Financial Officer & Head-Investor Relations|
|Monil Shah||Vice President-Clinical Research & Development|
|J. P. Benya||VP-Commercial Operations & Business Development|
|Diane E. Hague||Controller|